Provided are an injectable intraocular microgel and an injectable intraocular hydrogel that are safe to a human body and that can release a drug in the eye for a long period of time. This injectable intraocular microgel may have a form in which a drug is loaded on a hyaluronic acid microgel generated by causing hyaluronic acid copolymers to cross-link with each other through a w/o emulsion method.

The present invention relates to a contact lens for diagnosis and treatment of dry eye syndrome. The contact lens, according to the present invention, may diagnose dry eye syndrome by means of a change in an electric current occurring as a result of a field effect when a dry eye syndrome biomarker binds to a probe, and when dry eye syndrome is diagnosed, generates an electric current so that a gold film blocking a drug reservoir melts by the electric current, thereby enabling the release of a drug to be controlled.

In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, the disclosure relates to an auto-injector device that can be used for injection of ophthalmological formulations. The auto-injector device can function in two stages, where a lubricious material is released in a first stage and a drug delivery composition is released in a second stage. The present disclosure provides for method of using these injector devices.

The present disclosure relates to intraocular implants for treating a condition of the eye, wherein the implant is configured to deliver a drug to the eye. The present disclosure also relates to methods of treating a condition of the eye by delivering a drug from intraocular implants to the posterior chamber (e.g., sulcus), iridocorneal angle, sclera, cornea, limbus, and vitreous.

An implantable delivery device for dispensing a medicament that includes a first microporous material that is bonded to a second microporous material. The first microporous material has a first microporous layer including a plurality of pores sized to permit tissue ingrowth and a second microporous layer including a plurality of pores sized to permit tissue ingrowth. The second microporous material has a third microporous layer including a plurality of pores sized to resist tissue ingrowth and a fourth microporous layer including a plurality of pores sized to permit tissue ingrowth. The second microporous layer is bonded to the third microporous layer to thereby form a reservoir for receiving the medicament. The first and second microporous materials are configured to meter a rate at which the medicament is dispensed from the reservoir when the delivery device is implanted.

Described are implantable therapeutic devices, systems and methods to treat a patient. The device includes a hollow refillable housing for implantation within the posterior segment of an eye through a penetration in the sclera including a proximal retention structure protruding outward from a proximal end region of the housing, an access portion opening, and a penetrable barrier positioned at least in part within the access portion opening, the penetrable barrier configured to be repeatedly penetrated. A rigid porous structure is positioned within a region of the housing away from the access portion opening into a reservoir chamber extends along an axis between the penetrable barrier and the porous structure includes a volume sized to deliver therapeutic amounts of a therapeutic agent to the eye for an extended period of time. A cover is coupled to at least an upper surface of the proximal retention structure.

Provided is a smart contact lens for non-invasive drug delivery including a platform configured to be worn on an eye, a reservoir installed within the platform, and having a receiving part in which a drug is received, to provide the eye with the drug, an electrode for iontophoresis installed in the reservoir to make iontophoresis work, to provide the eye with the drug from the reservoir, and an activation chip electrically connected to the electrode for iontophoresis to activate iontophoresis.

An injector (1) for implanting a sensor implant (2) in the human or animal eye, in particular for the suprachoroidal implantation of a pressure sensor for the wireless measurement of the intraocular pressure, is improved in terms of rapid, complication-free, low-trauma and low-wear suprachoroidal implantation in that, to accommodate the sensor implant, the injector (1) has a substantially tubular injection chamber (8), the inner wall surfaces (9, 10) of which have a non-rotationally symmetrical cross section, preferably an oval or rectangular cross section, in that, at a free end, the injection chamber (8) is provided with an injection opening (13), through which, during implantation, the sensor implant (2) can slide out and slide into a sclera incision in the eye, wherein the inner wall surfaces (9, 10) of the injection chamber (8) enclose the likewise non-rotationally symmetrical cross section of the sensor implant (8) and prevent a rotation of the sensor implant (2) about an axis of rotation extending in the direction of the injection (11).

This invention privilege patent belongs to the field of medicine and surgical instruments, and is intended to provide a new route of drug administration through needles plated with specific metals, aiming at better drug distribution and absorption upon administration, more precisely in the eyeball and/or on the patient's skin; to which the product has been originally improved in order to increase its efficacy in relation to other means of drug delivery known in the medical field, especially in skin, mucous and ocular diseases; it is an improvement that allows drug delivery to the skin and/or subcutaneous tissue, by means of a duly modified tattoo machine, which instead of ink, uses drugs, as a product to be inserted in the skin; in addition, this invention can be used to administer drugs directly to a person's eyeball, offering great practicality and agility to surgical procedures.

An ocular implant for treating glaucoma is provided, which may include any number of features. More particularly, the present invention relates to implants that facilitate the transfer of fluid from within one area of the eye to another area of the eye. One feature of the implant is that it includes a proximal inlet portion and a distal inlet portion adapted to be inserted into the anterior chamber of the eye, and an intermediate portion adapted to be inserted into Schlemm's canal. Another feature of the implant is that it can be biased to assume a predetermined shape to aid in placement within the eye.